If a new treatment appears to improve median overall survival in a group of patients, is there any way to determine whether this improvement results from 'all' those treated surviving a few months longer, or whether it results from only a few individuals benefiting for a much longer time than the median (i.e. basically being 'cured'), while the majority receive no benefit from the treatment? Presumably both scenarios could give a similar apparent survival improvement.